Pacific Biosciences of California Inc reports results for the quarter ended in September - Earnings Summary

Pacific Biosciences of California

30/10/2023 21:02

* Pacific Biosciences of California Inc  PACB.OQ  reported a
quarterly adjusted loss of 26 cents​​ per share for the quarter
ended in September. The mean expectation of eleven analysts for
the quarter was for a loss of 33 cents per share.
    * Revenue rose 72.4% to $55.69 million from a year ago;
analysts
expected $48.76 million. 
    * Pacific Biosciences of California Inc's reported EPS for
the
quarter was a loss of 26 cents​.
    * The mean earnings estimate of analysts had fallen by
about 9.1%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Pacific Biosciences of California Inc shares had fallen
by 14.9%
this quarter and lost 13.1% so far this year.
    * The company reported a quarterly loss of $66.87 million.
    * Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $13.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
October 30 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.33          -0.26          Beat
 Jun. 30 2023      -0.32          -0.28          Beat
 Mar. 31 2023      -0.33          -0.36          Missed
 Dec. 31 2022      -0.36          -0.37          Missed